A major milestone has been achieved in Ipca’s quest for a New Chemical Entity development in malaria.

CDRI compound 97/78 which Ipca is developing has been approved for Phase I Human Studies.

This is the first Investigational New Drug Application of Ipca approved by the regulatory authorities and thus is a milestone in Ipca’s history.